-+ 0.00%
-+ 0.00%
-+ 0.00%

JOHNSON & JOHNSON’S RYBREVANT FASPRO™ (AMIVANTAMAB AND HYALURONIDASE-LPUJ) RECEIVES U.S. FDA PRIORITY REVIEW AS POTENTIAL FIRST-IN-CLASS EGFR- AND MET-TARGETED SUBCUTANEOUS TREATMENT FOR ADVANCED HEAD AND NECK CANCER

Reuters·07/30/2026 12:30:48

Please log in to view news